Zai Lab Limited Overview
ZLAB market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
- O
- 22.69
- H
- 22.80
- L
- 22.14
- C
- 22.28
- Vol
- 31,551.00
Daily history from Sep 20, 2017
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $22.69
- Previous Close
- $22.81
- Day High
- $22.80
- Day Low
- $22.14
- 52 Week High
- $27.45
- 52 Week Low
- $15.97
- 7 Day Return
- -0.38%
- 30 Day Return
- -13.06%
- 90 Day Return
- -4.46%
- 1 Year Return
- -10.13%
- Daily Notional Volume
- $702.8K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.16 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.15 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -41.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $12.31 – $21.42 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $21.1B · P/B 2.75 · P/S 5.97.